FOLH1 and neoplasm: Nonetheless, those findings had no relevant impact on the mean absorbed tumour doses ([177Lu]Lu-PSMA I&T: 5.8 Gy/GBq, [177Lu]Lu-PSMA-617: 5.9 Gy/GBq) [15], which may explain comparable outcome benefits for both agents observed in our study.